TICKERNOMICS Sign up
Last Update: 2024-12-27 15:21:28
BRISTOL MYERS SQUIBB CO ( BMY ) https://www.bms.com
58.29USD
Sector:
Healthcare
Industry:
Drug Manufacturers-General
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
BMY
17.92%
SPY
32.66%
BMY
6.06%
SPY
108.59%
BMY
16.99%
SPY
302.52%
BMY
66.21%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
118270.41
159340.00
4.69
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-16.30
2.49
6.84
13.57
4.14
7.56
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
38.50
75.13
44.04
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.9024
18.76
21.12
0.43
Other Earnings and Cash Flow Stats:
BRISTOL MYERS SQUIBB CO ( BMY ) Net Income TTM ($MM) is -7258.00
BRISTOL MYERS SQUIBB CO ( BMY ) Operating Income TTM ($MM) is 12717.00
BRISTOL MYERS SQUIBB CO ( BMY ) Owners' Earnings Annual ($MM) is 0.00
BRISTOL MYERS SQUIBB CO ( BMY ) Current Price to Owners' Earnings ratio is 0.00
BRISTOL MYERS SQUIBB CO ( BMY ) EBITDA TTM ($MM) is 20475.00
BRISTOL MYERS SQUIBB CO ( BMY ) EBITDA Margin is 44.04%
Capital Allocation:
BRISTOL MYERS SQUIBB CO ( BMY ) has paid 2.40 dividends per share and bought back 35.0 million shares in the past 12 months
BRISTOL MYERS SQUIBB CO ( BMY ) has increased its debt by 10335.0 million USD in the last 12 months
Capital Structure:
BRISTOL MYERS SQUIBB CO ( BMY ) Interest-bearing Debt ($MM) as of last quarter is 49752
BRISTOL MYERS SQUIBB CO ( BMY ) Annual Working Capital Investments ($MM) are -2297
BRISTOL MYERS SQUIBB CO ( BMY ) Book Value ($MM) as of last quarter is 17200
BRISTOL MYERS SQUIBB CO ( BMY ) Debt/Capital as of last quarter is 290%
Other Balance Sheet Stats:
BRISTOL MYERS SQUIBB CO ( BMY ) has 7890 million in cash on hand as of last quarter
BRISTOL MYERS SQUIBB CO ( BMY ) has 22638 million of liabilities due within 12 months, and long term debt 49547 as of last quarter
BRISTOL MYERS SQUIBB CO ( BMY ) has 2029 common shares outstanding as of last quarter
BRISTOL MYERS SQUIBB CO ( BMY ) has 0 million USD of preferred stock value
Academic Scores:
BRISTOL MYERS SQUIBB CO ( BMY ) Altman Z-Score is 2.29 as of last quarter
BRISTOL MYERS SQUIBB CO ( BMY ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
BRISTOL MYERS SQUIBB CO ( BMY ) largest shareholder is 1ST SOURCE BANK owning 30007 shares at 1.75 ($MM) value
Holzer Phil M(an insider) Sold 700 shares of BRISTOL MYERS SQUIBB CO ( BMY ) for the amount of $38930.50 on 2024-11-04
0.11% of BRISTOL MYERS SQUIBB CO ( BMY ) is held by insiders, and 79.33% is held by institutions
BRISTOL MYERS SQUIBB CO ( BMY ) went public on 1972-01-01
Other BRISTOL MYERS SQUIBB CO ( BMY ) financial metrics:
FCF:13803.00
Unlevered Free Cash Flow:0.00
EPS:2.39
Operating Margin:38.50
Gross Profit Margin:75.13
Div. Payout Ratio%:-67.09
Div. Growth YoY%:6.00
Equity Return%:28.26
Beta:0.43
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BRISTOL MYERS SQUIBB CO ( BMY ) :
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.